Navigation Links
Dermatologists Report Increased Use of Biologics in the Treatment of Psoriasis
Date:6/5/2008

EXTON, Pa., June 5 /PRNewswire/ -- BioTrends Research Group, Inc. released its third annual TreatmentTrends (TM): Psoriasis publication, providing insight into the management of psoriasis. This report is based on responses to an online survey completed by 102 US Dermatologists in April 2008.

According to the study, the majority of Dermatologists reported an increase in their use of biologics for the treatment of psoriasis in the past year, particularly in patients with moderate psoriasis. While the increased use of biologics was seen across the board, certain physician types, particularly those newer to practice, seem to be more aggressive in their use of these agents. Amgen/Wyeth's Enbrel continues to hold its position as market leader amongst the biologics, however, Abbott's Humira has increased its share significantly in the past year, and Dermatologists expect its growth to continue, primarily at the expense of Enbrel. Genentech/Xoma's Raptiva and Astellas' Amevive are rarely used with a collective share of less than 10%.

Despite the increased use of biologics, topical agents remain the most commonly prescribed therapy for psoriasis. Warner Chilcott's Taclonex, continues to hold its position as market leader among topical agents, although Galderma's Clobex is perceived to have significant advantages on certain attributes, most notably around its formulation. While the use of oral agents to treat psoriasis increases with disease severity, less than one-third of patients with severe psoriasis are on oral therapies. Methotrexate and Stiefel's Soriatane are the most commonly prescribed oral agents to treat psoriasis, and each is perceived to have unique advantages and disadvantages. Similar to oral agents, the use of phototherapy to treat psoriasis increases with disease severity, although only about one-fifth of patients with severe psoriasis are receiving phototherapy treatment.

For all treatment types (topicals, orals, biologics), long-term safety is the most important attribute. While all products fall short on this attribute compared to its importance, Dermatologists do perceive there to be significant safety differences between products in each product class, and perceived safety seems to be an important factor in brand preference. Moreover, in a ranking exercise of twelve attributes, "safe when used long term" was the attribute of greatest needs for new products in development to treat psoriasis. Time will tell whether the new IL-12 agents, such as Centocor's ustekinumab and Abbott's ABT-874 will be able to penetrate the TNF alpha inhibitor dominance in the Dermatology setting although interest in these agents is high.

About BioTrends Research Group, Inc.

BioTrends Research Group, Inc. (http://www.bio-trends.com) provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets.

All company, brand, or product names contained in this document may be trademarks of their respective holders.


'/>"/>
SOURCE BioTrends Research Group, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. QMed, Inc. Reports July Medicare SNP Enrollments
3. Phlo Affiliate Reports Expanded Coverage to Oregon Border
4. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
5. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
6. Carrington Reports Second Quarter 2007 Results
7. Avitar Reports Third Quarter Financial Results for Fiscal 2007
8. Response Genetics Reports Second Quarter 2007 Financial Results
9. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
10. Transgenomic, Inc. Reports Second Quarter 2007 Results
11. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back for ... June 2018 in San Francisco, CA. The Summit brings together current and former FDA ... board directors and government officials from around the world to address key issues in ...
(Date:10/11/2017)... a leading provider of patient support solutions, has announced the ... which will launch this week. The VMS CNEs will address ... enhance the patient care experience by delivering peer-to-peer education programs ... to help women who have been diagnosed and are being ... ...
(Date:10/11/2017)... ... ... Disappearing forests and increased emissions are the main causes of the evolving ... those living in larger cities are affected by air pollution related diseases. , That ... countries globally - decided to take action. , “I knew I had to take ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh ... orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of ... SBT-100 is able to cross the cell membrane and bind intracellular STAT3 and ...
Breaking Biology Technology:
(Date:6/23/2017)... N.Y. and ITHACA, N.Y. ... ) and Cornell University, a leader in dairy research, ... with bioinformatics designed to help reduce the chances that ... With the onset of this dairy project, Cornell University ... Consortium for Sequencing the Food Supply Chain, a food ...
(Date:5/23/2017)...  Hunova, the first robotic gym for the rehabilitation and functional motor ... Genoa, Italy . The first 30 robots will be ... USA . The technology was developed and patented at the ... spin-off Movendo Technology thanks to a 10 million euro investment from entrepreneur ... ...
(Date:5/16/2017)... DALLAS , May 16, 2017   ... for health organizations, and MD EMR Systems ... certified development partner for GE, have established a ... Patient Portal product and the GE Centricity™ products, ... Centricity EMR. These new integrations ...
Breaking Biology News(10 mins):